Articles tagged with Cancer Medication
A new oral drug intended to protect healthy tissue from radiation effects has been found safe for use in advanced non-small cell lung cancer patients. The agent, called manganese superoxide dismutase plasmid liposome, boosted antioxidant levels and reduced inflammation without protecting tumor cells.
A new clinical trial, sponsored by the National Cancer Institute, is testing whether rosuvastatin reduces the risk of recurrent colon cancer. The five-year study involves 1,740 patients and will determine if statins are effective in preventing colon cancer.
Scientists at Notre Dame and Cornell have made a breakthrough in understanding the genetic disorder Niemann-Pick Type C, which affects brain cells and causes devastating symptoms. Using histone deacetylase inhibitors, researchers were able to correct the damage done by the genetic flaw and restore normal cell function.
A study by Albert Einstein College of Medicine researchers found that an enzyme family, katanin, regulates cell motility. Treating this enzyme can encourage cells to migrate in a particular direction to heal wounds. This discovery could lead to new therapeutic agents for conditions like diabetic ulcers and metastatic cancer.
A Purdue University scientist has developed a nanopolymer that can detect the effectiveness of cancer drugs against biochemical processes leading to cancer cell formation. This innovation could replace radioisotopes and antibodies in screening kinase inhibitors, making it a universal method for pharmaceuticals.
Measuring mechanical strength of cancer cell mucus layers provides clues about treating cancer. Cancer cells produce excessive mucus, forming a barrier that prevents drugs from reaching them.
A new study sponsored by the National Heart, Lung, and Blood Institute found that sirolimus therapy can improve lung function and quality of life in individuals with lymphangioleiomyomatosis (LAM). The treatment was shown to slow disease progression and improve clinical outcomes in patients with this rare and progressive lung disease.
Research findings challenge traditional views on cancer treatment, revealing Cop1's role in tumor suppression rather than promotion. The study suggests that inhibiting Cop1 could stimulate cell proliferation in cancer cells.
Researchers at Dana-Farber Cancer Institute have found that a malaria drug, hydroxychloroquine, can slow the growth of pancreatic tumors in mice. The oral drug has been shown to decrease tumor growth by inhibiting autophagy, a survival strategy used by cancer cells.
A study published in Cancer suggests that tamoxifen can significantly reduce breast cancer risk in post-menopausal women under 55 with a high risk of developing the disease. The medication not only saves lives but also reduces medical costs, preventing 29 breast cancer cases and 9 deaths per 1,000 treated women.
A new treatment strategy using chemotherapy drugs Erlotinib and Gefitinib has been found to be effective in treating a subset of patients with advanced non-small-cell lung cancer. The drugs, which target the EGFR mutation, produced a response rate of over 70% and had fewer side effects compared to traditional treatments.
A Northwestern University research team found that binding chemotherapy drugs to nanodiamonds significantly improves the effectiveness of cancer treatment, particularly in cases where tumors are resistant to conventional therapies. The discovery holds promise for treating aggressive cancers with fewer toxic side effects.
Researchers at UT Southwestern Medical Center identified a chemical compound that may lead to a drug to combat cancers dependent on the anti-viral enzyme TBK-1. The compound, 6-aminopyrazolopyrimidine, was tested in mice and showed effectiveness in reducing cancer growth.
A novel clinical trial is exploring a new method to potentially prevent recurrence of early stage, aggressive breast cancer. The study is recruiting patients with HER-2 neu+ breast cancer and aims to identify high-risk patients who may benefit from an additional cancer-targeting drug.
Researchers from Scripps Research and MIT have discovered a class of extremely potent anti-cancer and anti-neurodegenerative disorder compounds. These compounds, including ABL127, were found using high-throughput screening and innovative testing techniques, and show promise for treating cancer and Alzheimer's disease.
Researchers have developed a molecular switch that enables efficient activation of dendritic cells, a crucial step in cancer vaccine development. By combining MyD88 and CD40 signaling pathways, the switch synergistically activates dendritic cells to enhance antitumor efficacy.
A new study found that 5a-reductase inhibitors can produce persistent erectile dysfunction, depression, and loss of libido in men, even after discontinuing the medication. Researchers urge patients and doctors to discuss these issues openly and assess the risk-benefit ratio prior to treatment.
A University of Georgia research team found that modifying a cell-surface protein called CNT1 can increase the effectiveness of gemcitabine, a common drug used to treat pancreatic cancer. By improving CNT1 function, researchers can help carry the drug into tumor cells and prevent proliferation.
Researchers have synthesized cancer literature to introduce the concept of enabling and emerging hallmarks, which are features that set the stage for cancer and may become core characteristics in nearly all cancers. This review article provides a cohesive foundation for biomedical researchers to develop new cancer treatments.
Researchers at Tel Aviv University discovered that curcumin amplifies the therapeutic activity of anti-inflammatory drugs used to treat colon cancer. This combination has already shown promising results in human clinical trials and may alleviate unwanted side effects.
Scientists from Thomas Jefferson University have discovered that the protein FADD controls multiple cell death pathways, which could lead to better treatment options for autoimmune diseases and cancer. The study found that FADD regulates apoptosis and keeps necrosis at bay, allowing researchers to develop more targeted drugs with fewer...
A new phase III trial has shown that erlotinib has comparable efficacy to chemotherapy in non-small cell lung cancer patients whose disease has progressed after first-line treatment. The study found no difference in overall survival or progression-free survival time between the two groups.
Researchers discovered that zoledronic acid can prevent lung cancer metastases from recruiting new blood vessels. The drug showed a statistically significant reduction in VEGF and b-FGF levels, suggesting potential anti-angiogenic effects.
A phase 3 study shows that denosumab delays and prevents bone events in men with castration-resistant prostate cancer, improving outcomes compared to zoledronic acid. Denosumab reduces the risk of bone fractures and other complications by inhibiting osteoclast activity.
Researchers discovered that targeting cancer-related pathways can treat congenital heart disease, with one drug reversing hypertrophic cardiomyopathy in mouse models. Two drugs, an immunosuppressant and anti-cancer agent, were found to be effective in preventing and reversing the condition.
Deakin University scientists develop RNA aptamer, a chemical antibody that targets cancer stem cells, aiming to deliver drugs directly to them. The aptamer has potential to revolutionize cancer detection and treatment with early-stage diagnosis and targeted therapy.
A 22-year study found no cases of diabetes and only one non-lethal case of cancer in individuals with Laron syndrome, a growth-stunting mutation. In contrast, relatives without such mutations had higher rates of diabetes and cancer. The study suggests that blocking growth hormone activity may be protective against these diseases.
Dr. Joseph M. DeSimone has mentored at least nine African American students, one Hispanic American student, and 24 women through the completion of their Ph.D. degrees in chemistry. He is being honored with the AAAS Mentor Award for his efforts to advance diversity in doctoral-level chemists entering the workforce.
Research at University of California, San Diego School of Medicine identifies regulatory T cells as primary source of RANKL protein, accelerating breast cancer spread. Interfering with RANKL interaction with cancer cells may block tumor progression, offering potential target for drug therapy.
Researchers have found that antioxidants can help prevent and treat breast cancer by targeting mitochondrial oxidative stress. The study, published in Cancer Biology & Therapy, used a genetically tractable model to show that loss of the tumor suppressor protein Caveolin-1 leads to increased oxidative stress, which fuels cancer cell gro...
Researchers have defined the cell of origin for sarcoma, a type of childhood and adult cancer. The study may lead to targeted therapies that convert cancer cells into normal ones.
Susan Band Horwitz has made significant contributions to cancer research, including the discovery of paclitaxel's mechanism of action and its role in treating various cancers. Her work on microtubules and drug resistance continues to advance our understanding of cancer treatments.
Researchers identify two distinct neuronal signaling pathways activated by Imiquimod, a topical cream that treats skin diseases while inducing severe itching as a side effect. The study may lead to designing future drugs that effectively treat targeted conditions while blocking problematic itching and scratching.
Researchers found that dutasteride is impractical due to high costs and marginal impact on survival and quality of life for at-risk groups. The medication's annual cost of $1,400 outweighs its benefits, making it less effective as a preventive measure.
A recent study published in BMJ Quality and Safety found that care home residents are more than four times as likely to get the wrong dose of medicine when it is in liquid form as they are when given pills/capsules. The study highlights the need for better training and systems to address this issue.
Researchers propose cancer cells employ ancient genetic pathways, a 'toolkit' from 1 billion years ago, to evade control and develop resistance. This concept offers new hope for personalized medicine and potentially reveals clues about life's history.
A team of researchers at the University of Gothenburg has identified an enzyme called GGTase-I that, when blocked, can lead to chronic inflammation and joint destruction in mice. The study suggests that GGTase-I plays a crucial role in suppressing RAC1 activity, which is behind the development of inflammatory disorders.
Researchers at Case Western Reserve University have developed a new chemotherapy method that targets cancer tumors more effectively by using gold nanoparticles to deliver an anti-cancer drug directly into the tumor. This approach allows for lower doses of toxic chemicals, reducing damage to healthy tissue.
A study published in Proceedings of the National Academy of Sciences found that low doses of losartan improved the effectiveness of two nanotherapeutic approaches against several types of cancer. Losartan normalized the abnormal extracellular matrix of tumors, allowing for better delivery and efficacy of therapies.
Bevacizumab, a cancer treatment drug, increases the risk of fatal adverse events (FAEs) when combined with chemotherapy or biological therapy. According to a review of published trials, the overall incidence of FAEs was 2.5%, with a significant increase in patients receiving taxanes or platinum agents.
Researchers at Memorial Sloan-Kettering Cancer Center have developed a novel ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer. The first-in-human clinical trial aims to evaluate the distribution, tissue uptake, and safety of the particles in humans using PET imaging.
Researchers from the University of Southampton are conducting Phase II trials for a new DNA vaccine targeting chronic and acute myeloid leukaemia, two forms of bone marrow and blood cancer. The vaccine aims to strengthen patients' immune systems and improve treatment outcomes.
Researchers have developed Cornell Dots, nanoparticles that can light up cancer cells to aid in diagnosis and treatment. The FDA has approved the first clinical trial of these dots in humans, which will verify their safety and effectiveness in treating melanoma.
A study from Henry Ford Hospital found that photodynamic therapy can preserve vocal cord function in patients with early-stage laryngeal cancer. The treatment, which uses a powerful laser and light-activated drug, showed consistent trends toward normal vocal cord vibration over several weeks and months.
Scientists successfully applied home device technology to increase solubility of anticancer drugs like tamoxifen and paclitaxel. The process has potential for improving performance of dyes, paints, rust-proofing agents and other products.
A new study found that 72% of patients in early-phase cancer trials accurately understood the trial purpose, but exhibited unrealistic optimism in response to specific questions. This bias may interfere with applying information realistically and compromise informed consent.
A study by Elisabetta Rapiti found that women taking tamoxifen had 87% fewer lung cancer deaths than the general population. The research supports a hormonal influence on lung cancer and estrogen's role in patients' prognosis.
Scientists at the University of East Anglia discovered a rogue gene, WWP2, that attacks and breaks down natural inhibitors preventing cancer cell spreading. Blocking WWP2 boosts these inhibitors, keeping cancer cells dormant.
The Creating Hope Act offers financial incentives to companies developing drugs for pediatric rare diseases. Pediatric specialists often prescribe adult therapeutics off-label due to limited research on child-specific treatments, leading to concerns about efficacy and safety.
Researchers identified 27 genes that influence the effectiveness of oxaliplatin in treating colorectal cancer. The study highlights the need for further clinical research to improve treatment outcomes and reduce side effects associated with the drug.
Researchers at The Peggy and Charles Stephenson Oklahoma Cancer Center have found a way to stop early stage pancreatic cancer in research models, offering a promising approach for high-risk patients. A clinical trial has been launched, and the FDA-approved drug Gefitinib is expected to be tested nationwide within a year.
Researchers at UNC Health Care have developed particles that closely mirror key properties of red blood cells, potentially paving the way for synthetic blood. The new discovery has also shown promise in treating life-threatening medical conditions like cancer.
A new experimental drug, morphine-6-0-sulfate, has been found to be more potent and longer-lasting than standard morphine, with less likelihood of causing constipation. The study, led by Dr. Joseph Holtman Jr., tested the drug on rats and demonstrated its potential clinical advantages compared to morphine.
Research reveals parallels between immunity and cancer, with acute inflammation compared to chronic inflammation in mammals. The immune system that counters parasitoid wasp infections is highly restrained, but goes haywire when regulating mechanism fails, leading to cancer development.
A new study led by researchers at WashU Medicine found that consistent exercise is associated with a lower risk of dying from colon cancer. The study analyzed data from over 150,000 men and women and found that those who exercised for at least 10 years had the lowest risk of colon cancer death.
Researchers found that endothelin-A receptor antagonist drugs only reduce tumor growth at metastasis sites, not large tumors. These drugs block the action of protein ET-1, which stimulates cancer cell growth and spread.
Researchers at Georgetown University Medical Center have found an arsenic-based agent already FDA-approved for a type of leukemia may be helpful in treating Ewing's Sarcoma and medulloblastoma. The drug inhibits the hedgehog/GLI1 pathway, which is also common in other cancers.
Researchers at the University of Arizona have developed a way to deliver chemotherapeutic drugs to cancer tissues in controlled doses without harming healthy body cells. The gold-coated liposomes can target specific receptors on tumor cells, allowing for more effective treatment and reduced side effects.
Researchers at the University of Pennsylvania School of Medicine have identified P-Rex1 as a crucial protein in signal transmission from ErbB receptors, driving breast cancer growth and metastasis. The study suggests that targeting this pathway could improve responses to existing therapies.
A new system using electronic health records significantly improves primary care physicians' performance and the health of patients with chronic conditions. The program boosts preventive care in vaccinations and cancer and osteoporosis screenings, increasing rates by up to 10 percentage points.